<DOC>
	<DOC>NCT02580370</DOC>
	<brief_summary>This is a safety and efficacy study of botulinum toxin type A in subjects with lateral canthal lines.</brief_summary>
	<brief_title>Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>In good general health Moderate to severe lateral canthal lines when evaluated at rest based on the investigator's global assessment Moderate to severe lateral canthal lines when evaluated at rest based on the patient assessment of severity Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A such as amyotrophic lateral sclerosis and motor neuropathy, LambertEaton syndrome, and myasthenia gravis Muscle weakness or paralysis, particularly in the area receiving study treatment Active skin disease or irritation or disrupted barrier at the treatment area Active eye disease or irritation Eyelid ptosis, excessive dermatochalasis, deep dermal scarring, or inability to substantially effect the LCL to be treated by manually spreading the skin apart Use of topical prescription retinoid product(s) in the lateral canthal areas during the 3 months prior to Screening Undergone any procedures that may affect the lateral canthal region during the 12 months prior to Screening Treatment with botulinum toxin type A in the lateral canthal areas in the 6 months prior to Screening or 3 months anywhere else in the body</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>REALISE 1</keyword>
</DOC>